Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

23.11.2015: AH: WILEX AG unveils financing strategy for further development of ADC technology and adopts capital measures. The Executive Management Board today adopted, with the approval of the Supervisory Board, a financing strategy that is expected to ensure the further development and marketing of ADC technology at the Company's subsidiary Heidelberg Pharma GmbH, initially until the end of 2016.  ....More




Seite gelesen: 408568 | Heute: 68